Study Design: This interventional study is randomized and follows a parallel assignment model. It is double-blind, meaning neither participants nor the care providers, investigators, or outcome ...

A new study by University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about ...

Enzalutamide monotherapy demonstrated significant treatment response among men on active surveillance for low- or intermediate-risk localized prostate cancer, according to phase 2 study results ...

"Enzalutamide in combination with ADT, if approved in this setting, has the potential to become new standard of care for patients with high-risk BCR," said Shore.

XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive prostate cancer ...

Today, Astellas Pharma Canada, Inc. announced that XTANDI® (enzalutamide) is now funded by the Ontario Drug Benefit Program under the Exceptional Access Program for the treatment of patients with ...

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

In a phase 3 clinical trial by Pfizer, treatment with talazoparib and enzalutamide lowered the risk of prostate cancer progression or death by 37%.

In a study of men with nmHSPC and high-risk BCR, enzalutamide plus leuprolide lowered metastasis risk compared with leuprolide plus placebo.

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients.

Talazoparib and enzalutamide combination reduces death risk by 20.4% in mCRPC patients, regardless of HRR status. The combination therapy offers survival benefits without increased toxicity ...